The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2009

Filed:

Jul. 14, 2003
Applicants:

Kenneth D. Rice, Mill Valley, CA (US);

Neel K. Anand, Burlingame, CA (US);

Joerg Bussenius, Foster City, CA (US);

Abigail R. Kennedy, San Leandro, CA (US);

Angie I. Kim, San Mateo, CA (US);

Csaba J. Peto, Alameda, CA (US);

Tsze H. Tsang, El Cerrito, CA (US);

Inventors:

Kenneth D. Rice, Mill Valley, CA (US);

Neel K. Anand, Burlingame, CA (US);

Joerg Bussenius, Foster City, CA (US);

Abigail R. Kennedy, San Leandro, CA (US);

Angie I. Kim, San Mateo, CA (US);

Csaba J. Peto, Alameda, CA (US);

Tsze H. Tsang, El Cerrito, CA (US);

Assignee:

Other;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 43/00 (2006.01); A61K 31/33 (2006.01); A01N 43/54 (2006.01); A61K 31/517 (2006.01); C07D 401/00 (2006.01); C07D 403/00 (2006.01); C07D 413/00 (2006.01); C07D 417/00 (2006.01); C07D 419/00 (2006.01); C07D 239/72 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include 'spectrum selective' kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.


Find Patent Forward Citations

Loading…